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Background: The pathological hallmark of multiple sclerosis (MS) is myelin phagocytosis. It remains unclear why
microglia and macrophages demyelinate axons in MS, but previously found or yet-unknown changes in the myelin
of MS patients could contribute to this process. We therefore studied whether myelin from normal-appearing white
matter (NAWM) of MS donors is phagocytosed more efficiently than myelin from control donors.
Methods: Myelin was isolated from 11 MS and 12 control brain donors and labeled with the pH-sensitive fluorescent
dye pHrodo to quantify uptake in lysosomes. Phagocytosis by differentiated THP-1 macrophages and by primary
human microglia was quantified with flow cytometry. Whereas myelin uptake by THP-1 macrophages reached a
plateau after approximately 24 hours, uptake by primary human microglia showed an almost linear increase over a
72–hour period. Data were statistically analyzed with the Mann–Whitney U test.
Results: MS-derived myelin was phagocytosed more efficiently by THP-1 macrophages after 6-hour incubation
(P = 0.001 for the percentage of myelin-phagocytosing cells and P = 0.0005 for total myelin uptake) and after 24-hour
incubation (P = 0.0006 and P = 0.0001, respectively), and by microglia after 24-hour incubation (P = 0.0106 for total
myelin uptake). This enhanced uptake was not due to differences in the oxidation status of the myelin. Interestingly,
myelin phagocytosis correlated negatively with the age of myelin donors, whereas the age of microglia donors showed
a positive trend with myelin phagocytosis.
Conclusions: Myelin isolated from normal-appearing white matter of MS donors was phagocytosed more efficiently
than was myelin isolated from control brain donors by both THP-1 macrophages and primary human microglia.
These data indicate that changes in MS myelin might precede phagocyte activation and subsequent demyelination in
MS. Identifying these myelin changes responsible for enhancing phagocytic ability could be an interesting therapeutic
target to prevent or inhibit formation or expansion of MS lesions. Moreover, during aging, microglia enhance their
phagocytic capacity for myelin phagocytosis, but myelin reduces its susceptibility for uptake.
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Demyelination is the pathologic hallmark of multiple
sclerosis (MS) [1], but the initial cause that triggers resi-
dent microglia and infiltrating macrophages to start
phagocytosing myelin remains to be elucidated. Many
studies focused on phagocytic cells to stop them as* Correspondence: i.huitinga@nin.knaw.nl
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unless otherwise stated.effector cells in demyelination [2], but relatively little re-
search focused on the myelin itself.
Different studies have reported altered myelin oxida-
tion in multiple sclerosis. Lipid peroxidation-derived
malondialdehyde (MDA) was increased in and around
active MS lesions [3], and rat MDA-modified myelin
oligodendrocyte glycoprotein (MOG) was phagocytosed
more efficiently than was naïve MOG via scavenger re-
ceptor (SR) class A on mouse macrophages [4]. 4-
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white matter (NAWM) of MS donors compared with
myelin isolated from control donors [5]. Lipid peroxida-
tion might create new ligands for SRs that are known to
bind oxidized low-density lipoproteins (oxLDLs) and ox-
idized phospholipids on apoptotic cells [6,7]. In line
herewith, SRs have been suggested to play a role in mye-
lin phagocytosis [4,8-12] or the animal model of multiple
sclerosis, experimental autoimmune encephalomyelitis
(EAE) [13,14]. Myelin lipid composition is also altered in
NAWM of MS donors, and autoantibodies to several
myelin lipids were elevated in sera of MS donors
(reviewed in [15]).
Besides myelin lipids, myelin proteins are also subject to
changes in MS. Myelin basic protein (MBP) isolated from
NAWM of MS donors is overall less phosphorylated and
more methylated and citrullinated than MBP of control
donor WM [16]. These posttranslational modifications
alter membrane stability, making MBP more susceptible
for proteases, which might eventually create neo-self anti-
gens that induce disease. Increased activity of peptidylargi-
nine deiminases (PADs), enzymes generating citrulline,
and increased protein citrullination was found in NAWM
of MS donors [17]. 2-Chloroacetamidine, a PAD inhibitor,
reduced PAD activity in human brain extracts and attenu-
ated disease in four different demyelinating mouse models,
indicating that citrullination determines severity of dis-
ease. However, no anti-citrullinated protein antibodies
were found in serum of MS patients [18], indicating that
citrullination itself is not a direct target for autoimmunity
in multiple sclerosis.
Opsonization might also mark myelin for phagocytosis.
Expression of the complement factors C3d, C4d, and
C3b was enhanced on myelin of MS lesions and often
colocalized with HLA+ macrophages [19,20]. Complement
opsonization is known to increase myelin phagocytosis
in vitro [10-12,21]. Myelin-directed autoantibodies can also
opsonize myelin and increase its uptake in vitro [10,21,22].
Finally, heat-shock protein 70 (hsp70) was found to be as-
sociated with MBP and proteolipid protein (PLP) in chronic
active MS lesions and association with MBP increased up-
take and presentation by different phagocytes in vitro [23].
Moreover, hsp70 directly enhanced the phagocytic capacity
of macrophages [24], and the small heat-shock protein αB-
crystallin was identified as immunogenic protein in mul-
tiple sclerosis-affected myelin [25] and in NAWM of preac-
tive lesions of MS patients [26].
We hypothesized that the changes found in MS myelin
could increase its uptake compared with myelin from
controls without neurologic abnormalities. To test this
hypothesis, we isolated myelin from NAWM of 11 MS
and 12 control donors immediately postmortem and
quantified its phagocytosis by macrophages and micro-
glia. Myelin was labeled with pHrodo, a pH-sensitive dyeused previously to detect engulfment of apoptotic cells
[27]. The pHrodo-conjugated myelin allowed us to quan-
tify material taken up into the acidic milieu of the phago-
lysosomes while excluding material attached to the cell
surface. We showed that MS myelin is phagocytosed more
efficiently by macrophages derived from the human
monocytic cell line THP-1 and by primary human mi-
croglia, indicating that aforementioned or yet-unknown
changes within MS myelin can trigger phagocytosis.
Materials and methods
Human brain tissue
Postmortem human brain tissue was provided by
the Netherlands Brain Bank (NBB, Amsterdam, The
Netherlands). Permission was obtained from donors
for brain autopsy and the use of tissue and clinical in-
formation for research purposes. At autopsy, the corpus
callosum and/or subcortical white matter was dissected
and stored in Hibernate A medium (Brain Bits LLC,
Springfield, IL, USA) until further processing. The absence
of lesions in MS NAWM was confirmed by scanning brain
slices with T2 or 3D-FLAIR MRI [28]. Myelin was isolated
from 11 MS and 12 donors without neurologic abnormal-
ities (Table 1). The mean age of MS donors was 62.6 years
(range, 50 to 73 years), and for control donors, 80.2 years
(range, 60 to 94 years). The mean postmortem delay
(PMD) was 8:47 hours for MS donors (range, 7:05 to
10:40 hours) and 6:13 hours for control donors (range,
4:15 to 8:35 hours). The mean pH of the cerebrospinal
fluid (CSF) was 6.46 for MS donors (range, 6.16 to 7.10)
and 6.51 for control donors (range, 6.03 to 7.07).
Microglia were isolated from different donors (five
controls, three with Parkinson disease, one with MS, and
one with frontotemporal dementia) (Table 2). The mean
age was 72.8 years (range, 57 to 89 years); the mean
PMD was 6:07 (range, 3:45 to 10:45 years), and the mean
CSF pH was 6.51 (range, 6.2 to 6.73).
Microglia isolation
Microglia isolation was performed as described previ-
ously [29,30]. In brief, tissue was mechanically and enzy-
matically dissociated, and erythrocytes were lysed. Cells,
myelin, and debris were then separated by density gradi-
ent separation by using Percoll (GE Healthcare, Uppsala,
Sweden) of ρ = 1.03 and ρ = 1.095 and buffer. Myelin
was either discarded or collected from the buffer and
Percoll ρ = 1.03 interlayer and stored until further pro-
cessing. Cells were collected from the Percoll ρ = 1.03
and ρ = 1.095 interlayer and counted. Microglia were
further isolated by magnetic bead sorting (Miltenyi Bio-
tec GmbH, Bergisch Gladbach, Germany) by using
CD15 beads for negative selection to remove granulo-
cytes and subsequent CD11b beads for positive selection
of microglia. The purity of the isolated microglia and
Table 1 Detailed information of myelin donors
NBB F/M Age PMD pH Diagnosis Disease duration Disease course Treatment last 3 months
2010-005 F 68 10:40 6.4 MS 57 RR-SP
2010-045 F 84 07:35 - MS 50 PR
2010-117 F 60 10:40 6.48 MS 7 SP
2011-008 M 54 08:15 6.39 MS 12 PP
2011-035 F 50 07:35 6.45 MS 17 SP
2011-048 M 53 10:00 6.38 MS 24 SP
2011-080 F 56 08:25 6.16 MS 32 SP Vitamin D
2011-089 M 64 07:30 6.49 MS 35 RR-SP
2011-093 M 56 10:10 7.1 MS 13 RR
2011-100 F 71 07:05 6.32 MS 31 RR-SP
2011-120 M 73 08:45 6.4 MS 42 SP β-interferon
2010-007 F 85 05:20 7.07 HC - -
2010-062 F 94 05:50 7.04 HC - -
2010-068 M 85 08:35 6.04 HC - -
2010-070 F 60 07:30 6.8 HC - -
2011-021 F 85 07:05 - HC - -
2011-039 F 91 04:15 6.5 HC - -
2011-046 F 89 04:45 6.67 HC - -
2011-049 F 83 04:40 6.04 HC - -
2011-091 M 76 06:45 6.31 HC - -
2012-048 M 81 06:40 6.7 HC (depression) - -
2012-049 F 70 07:35 6.03 HC - -
2012-052 F 64 05:40 6.35 HC - -
F/M, female/male; HC, healthy control; MS, multiple sclerosis; NBB, Netherlands Brain Bank donor number; PMD, postmortem delay; PP, primary progressive MS;
RR, relapsing remitting MS; SP, secondary progressive MS.
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(see later). Microglia were cultured in RPMI glutaMAX
medium containing 10% fetal calf serum (FCS) and 1%
penicillin/streptomycin (all Invitrogen, Carlsbad, CA,
USA) and allowed to adhere before myelin incubation.Table 2 Detailed information of microglia donors
NBB F/M Age PMD pH Diagnosis
2012-071 F 57 7:40 6.47 HC
2012-080 M 86 5:50 6.48 PD
2012-091 F 61 5:55 6.63 PD
2012-101 M 80 4:25 6.59 HC
2012-104 M 79 6:30 6.3 HC (personality disorder)
2012-113 M 59 10:45 6.5 MS
2013-003 M 60 5:00 6.2 PD
2013-008 F 74 3:45 6.55 FTD
2013-010 F 89 6:35 6.73 HC
2013-016 M 83 5:15 6.6 HC
F/M, female/male; FTD, frontotemporal dementia; HC, healthy control; MS,
multiple sclerosis; NBB, Netherlands Brain Bank donor number; PD, Parkinson
disease; PMD, postmortem delay.Myelin isolation and labeling
The myelin-containing fraction was collected after Percoll
gradient separation (see Microglia isolation) and further
purified by a sucrose gradient, as described previously [31].
The myelin fraction was washed thrice in 0.32 M sucrose
(Sigma-Aldrich, St. Louis, MO, USA), resuspended in 0.32
M sucrose, and underlain with 0.85 M sucrose. This gradi-
ent was centrifuged for 50 minutes at 4,500 g. Myelin was
collected from the interface and washed in water to induce
an osmotic shock to remove any remaining cells. After
centrifugation, myelin was collected, resuspended in PBS,
and stored at -80°C until further processing.
Myelin concentration was measured with the bicinch-
oninic acid (BCA) protein assay kit (Pierce Thermo Sci-
entific, Rockford, IL, USA). For all samples, endotoxin
content was measured with the Toxin sensor LAL endo-
toxin assay kit (Genscript USA Inc, Piscataway, NJ,
USA). Most samples stayed under the detection limit of
0.05 EU/ml, and the small amount of endotoxin (0 to
0.019 EU/ml per μg myelin) found in some samples did
not correlate with myelin phagocytosis. Myelin was la-
beled with the pH-sensitive dye pHrodo red, succinimidyl
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take in the lysosomal compartment [27]. The pHrodo dye
was dissolved in 1 ml dimethyl sulfoxide (DMSO) and
used 1:100 per milligram myelin. Myelin was resuspended
in PBS, pH 8, and incubated with pHrodo for 45 minutes
at RT. Labeled myelin was spun down and resuspended in
PBS pH 7.4 and stored at -80°C. The labeling efficiency of
individual myelin samples was measured by resuspending
labeled myelin in PBS with pH 4 and measuring fluores-
cence on a Varioskan Flash (excitation, 530, and emission,
560/585 nm).Cell culture and phagocytosis assay
The human monocytic cell line THP-1 was cultured in
RPMI glutaMAX medium containing 10% FCS and 1%
penicillin/streptomycin. Cells were cultured in plates
coated with poly (2-hydroxyethyl methacrylate), other-
wise known as hydron (Sigma-Aldrich), to prevent ad-
herence. Cells were differentiated into macrophage-like
cells by stimulation with 160 nM phorbol myristate acet-
ate (PMA) for 24 hours, followed by another 24-hour
culture in normal medium.
For phagocytosis assays, THP-1 macrophages were in-
cubated with 12.5 μg pHrodo-labeled myelin per 80,000
cells for either 6 or 24 hours. Microglia were incubated
with 1 μg pHrodo-labeled myelin per 90,000 cells for
24 hours. After incubation, cells were collected (THP-1
macrophages were free floating, and microglia were de-
tached by 5-minute incubation in 25 mM EDTA at
37°C) and washed in cold PBS with 1% BSA and stained
for flow-cytometric analysis.Flow cytometry
Primary microglia were stained immediately after isolation
with anti-human CD11b-PE (clone ICRF44; eBioscience,
San Diego, CA, USA) and anti-human CD45-FITC (clone
HI30; Dako, Glostrup, Denmark) for 30 minutes on ice to
assess their initial activation status ex vivo. The viability
marker 7-amino-actinomycin D (7-AAD; BD Biosciences)
was added approximately 10 to 15 minutes before analysis
on the FACScalibur machine (BD Bioscience).
For the quantification of myelin uptake, THP-1 macro-
phages and microglia were collected as described before
and incubated 1:2,000 with the viability dye eFluor 780
(eBiosciences) for 30 minutes on ice. Uptake of pHrodo-
labeled myelin was measured on a FACSCanto machine
(BD Biosciences), by using identical settings for either
THP-1 or microglia, and analyzed by using FlowJo 7.6
software. Phagocytosis was expressed as percentage of
live cells that took up myelin and as geomean fluores-
cence intensity (geoMFI) of the pHrodo signal, indicat-
ing the total amount of myelin phagocytosed. Doublets
were excluded in the microglia phagocytosis assays.TBARS (lipid peroxidation) assay
Lipid peroxidation of the myelin samples was deter-
mined by measuring MDA in a thiobarbituric acid-
reactive substances (TBARS) assay. The 200 μg myelin
was resuspended in 100 μl PBS, pH 7.4, and incubated
with 200 μl ice-cold 10% trichloroacetic acid (TCA;
VWR International, Lutterworth, England) for 15 mi-
nutes on ice to precipitate protein. Then, 300 μl 0.67%
2-thiobarbituric acid (TBA) in 10% DMSO was added,
and samples were incubated at 99°C on a heat plate for
15 minutes. After incubation, samples were spun down
at 2,200 g for 15 minutes at 4°C and left to cool. Fluores-
cence (excitation 530 and emission 550 nm) was mea-
sured in duplo against an MDA standard (ranging from
50 pM to 5 nM; Sigma-Aldrich) on a Varioskan Flash
(ThermoScientific, Waltham, MA, USA).
Image acquisition
Fluorescent images were taken on an AxioVert micro-
scope (Zeiss, Oberkochen, Germany) with Neoplanfluor
objectives by using an Exi Aqua Bio-imaging microscopy
camera (QImaging, Surrey, BC, Canada) and ImagePro
software (MediaCybernetics, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed by using GraphPad
Prism version 5 software (GraphPad Inc., La Jolla, CA,
USA). Differences between individual samples were
assessed with the Mann–Whitney U test. Correlations
between two continuous parameters were assessed with
the Spearman correlation coefficient. P values <0.05
were considered significant.
Results
Analysis of pHrodo-labeled myelin internalization by THP-
1 macrophages and primary human microglia
Myelin conjugated with the pH-sensitive dye pHrodo emit-
ted a red fluorescent signal as pH decreased (Figure 1A),
which enabled detection of its uptake into the acidic milieu
of the phagolysosomes by flow cytometry. This method
has already been successfully used to study the uptake
of apoptotic cells [27]. pHrodo itself did not have any
effect on the phenotype of THP-1 macrophages (data
not shown). A distinct pHrodo-positive cell population
formed when THP-1 macrophages were incubated with
pHrodo-labeled myelin for 6 and 24 hours compared
with control cells (Figure 1B). The shift in fluorescent
signal of the pHrodo-negative population compared
with control cells after 24 hours is due to a decrease in
pH of the medium, causing the bound nonphagocytosed
myelin slightly to increase fluorescence (about 135% as
measured on a Varioskan Flash). Phagocytosed pHrodo-
labeled myelin was clearly visible in vesicles in both
THP-1 macrophages (Figure 1C) and in primary human
Figure 1 Quantification of myelin phagocytosis by using a pH-sensitive fluorescent dye. (A) Myelin was labeled with pHrodo and
resuspended in PBS pH 7.4, 6, or 4. Fluorescent intensity was measured on a Varioskan Flash and increased in signal with decreasing pH. (B)
THP-1 macrophages were incubated without (gray line) or with 12.5 μg pHrodo-labeled myelin (black line) for 6 and 24 hours, and measured with
flow cytometry. Fluorescence increased over time as THP-1 macrophages phagocytosed myelin. Uptake of pHrodo-labeled myelin (red) by (C)
THP-1 macrophages and by (D) primary human microglia. Microglia were stained with phalloidin (green) to visualize actin filaments. Insert shows
a close-up of a phagocytosing microglia. (E) Percentage of cells that phagocytosed pHrodo-labeled myelin in (E). THP-1 macrophages and (F)
primary human microglia over time measured with flow cytometry. Scale bar is 25 μm.
Hendrickx et al. Journal of Neuroinflammation 2014, 11:64 Page 5 of 11
http://www.jneuroinflammation.com/content/11/1/64microglia (Figure 1D). In contrast, myelin that was not
phagocytosed, visualized by bright field, was not or was
barely fluorescent (see Additional file 1).
Next, the optimal incubation time for quantifying
myelin uptake by THP-1 macrophages (Figure 1E) and
primary human microglia (Figure 1F) was determined.
THP-1 macrophages were incubated with pHrodo-
labeled myelin (from donors with different neurologic
backgrounds) for 2, 4, 6, 8, 24, 48, and 72 hours, and the
percentage of cells that phagocytosed myelin was mea-sured with flow cytometry. As shown, phagocytosis peaked
at 24 hours, after which a plateau was reached. This in-
dicates that either THP-1 does not phagocytose more
myelin or an equilibrium is reached between uptake
and breakdown. For further experiments, THP-1 mac-
rophages were incubated for 6 hours and for 24 hours,
to measure progressing and peak phagocytosis, respect-
ively. Microglia were incubated with pHrodo-labeled
myelin (from donors with different neurologic back-
grounds) for 2, 4, 6, 24, and 72 hours. Contrary to
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continuous process that did not saturate within 72 hours,
the latest time point measured. However, because of
increased cell death at this time point, phagocytosis was
measured after 24 hours in further experiments. The time
dynamics of myelin phagocytosis (pHrodo signal) during
pilot studies was the same in either THP-1 macrophages
or human microglia, independent of the neurologic back-
ground of the myelin donors. This indicates that differ-
ences found in uptake of MS and control donor myelin at
specific time points is not a result of differences in phago-
cytosis speed or endosomal acidification, as this would
result in a shift in the timeline experiments.
The fluorescent intensity of individual myelin samples
was measured at pH 4. Labeling efficiency varied slightly
between the myelin samples used, but no correlation
was found between the fluorescence of myelin samples
at pH 4 and the fluorescence intensity of cells that had
taken up these myelin samples (percentage of fluores-
cent cells and total amount of myelin uptake expressed
as the geoMFI), indicating that labeling efficiency did
not influence the phagocytosis results (not shown).
Increased phagocytosis of multiple sclerosis-derived myelin
THP-1 macrophages were incubated with pHrodo-
labeled myelin samples from NAWM of 11 MS and 12
control donors for 6 hours and 24 hours, and phagocyt-
osis by viable cells was measured by using flow cytome-
try (Figure 2A). At 6 hours and 24 hours, a shift toward
more uptake of MS myelin was detected (Figure 2B).
Both the percentage of cells that had phagocytosed mye-
lin and the amount of myelin taken up by the cells were
significantly higher when cells were incubated with MS
myelin as compared with control myelin after 6 hours
(P = 0.001 and P = 0.0005, respectively) and 24 hours
(P = 0.0006 and P = 0.0001, respectively) (Figure 2C).
Next, we measured uptake of the myelin samples by
primary microglia isolated from fresh human brain tis-
sue. Microglia were isolated from NAWM of 10 brain
donors and incubated for 24 hours with the 11 MS and
12 control myelin samples. Myelin phagocytosis by vi-
able cells was assessed with flow cytometry (Figure 3A).
Again, a shift was observed toward more uptake of MS
myelin (Figure 3B). Quantification of the uptake of the
individual myelin samples by the 10 microglia isolates
revealed no significant difference in the percentage of
pHrodo-positive cells (P = 0.4791). However, an increase
was observed in the amount of myelin taken up (P =
0.0106) when cells were incubated with MS myelin as
compared with control myelin (Figure 3C).
Because the microglia studied here were isolated from
donors with different ages, we compared their phagocyt-
osis capacity. We observed a trend toward an increase in
myelin uptake (percentage and total amount) with donorage (see Additional file 2). Of note, the initial activation
status of the isolated microglia, based on CD11b and
CD45 expression analyzed with flow cytometry, did not
correlate with myelin uptake (data not shown).
MDA, a measurement of lipid peroxidation, was not
significantly different between myelin samples from MS
and control donors, nor did it correlate with myelin
phagocytosis in our experiments (data not shown).
Effect of age and PMD of myelin donors on phagocytosis
Myelin was isolated as donors came to autopsy and was
therefore not matched for age and PMD initially. Age
(MS, 62.6 ± 10.4 years; controls, 80.2 ± 10.7 years) and
PMD (MS, 8:47 ± 1:21 hours; controls, 6:13 ± 1:21 hours)
differed significantly between MS and control donors
(P = 0.0023 and P = 0.0008, respectively) (see Additional
file 3A), due to earlier death of MS donors and the post-
mortem MRI performed on brain slices of MS patients.
Because both age and PMD also correlated with myelin
uptake (Additional file 3B and C), they could have influ-
enced phagocytosis efficacy in our assays.
To correct for age and PMD retrospectively, we com-
pared myelin phagocytosis between myelin samples
matched for age or PMD (Additional file 3C). Within
the age-matched subgroup, comprising six MS and nine
control myelin samples, an increase was still observed in
the percentage of MS myelin-phagocytosing THP-1
macrophages and total MS myelin uptake after 6 hours
(P = 0.0120 and P = 0.0016, respectively) and 24 hours
(P = 0.0004 and P = 0.0008, respectively) incubation (Table 3
and Additional file 3D). Similarly, increased uptake of
MS myelin by THP-1 macrophages was observed in the
PMD-matched subgroup, comprising seven MS and six
control myelin samples, after 6 hours (P = 0.0023 for
percentage and P = 0.0082 for total uptake) and 24 hours
(P = 0.0082 for percentage and P = 0.0023 for total uptake)
incubation (Table 3 and Additional file 3D). Analysis
of the same age-matched myelin samples revealed a
significantly enhanced total uptake of MS myelin by
primary microglia (P = 0.0496). However, significance was
lost within the PMD-matched myelin samples (P = 0.0734),
probably because of a decrease in power, although a trend
still remained. We concluded that MS myelin is taken
up more efficiently than control myelin, irrespective of
donor age and PMD.
Discussion
We are the first to show that myelin from NAWM of MS
brain donors is taken up more efficiently than myelin from
control donors by the human macrophage cell line THP-1
and by primary human microglia. Both the percentage of
cells that had phagocytosed myelin and the total amount
of myelin phagocytosed by the cells were significantly
higher in THP-1 macrophages incubated with MS myelin
Figure 2 (See legend on next page.)
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Figure 2 Increased uptake of MS myelin by THP-1 macrophages after 6 and 24 hours. (A) Flow-cytometric analysis of live cells defined
by forward and sideward scatter (FSC and SSC) characteristics and the viability dye eFluor for uptake of pHrodo-labeled myelin after 6 and
24 hours of incubation. (B). Histograms showing uptake of 11 MS and 12 control myelin samples (pHrodo signal) after 6 and 24 hours. (C)
THP-1 macrophages phagocytosed MS myelin more efficiently than control myelin after 6 and 24 hours. Both the percentage of cells that took
up myelin and the amount of myelin taken up (geoMFI) was significantly higher when cells were incubated with MS myelin. Shown is the
mean for each myelin sample in four independent experiments. Data were analyzed with the Mann–Whitney U test. HC, healthy control; MS,
multiple sclerosis. * < 0.05; ** < 0.005; *** < 0.0005.
Hendrickx et al. Journal of Neuroinflammation 2014, 11:64 Page 8 of 11
http://www.jneuroinflammation.com/content/11/1/64compared with control myelin after 6 and 24 hours. After
6 hours, the percentage of phagocytosing cells was still in-
creasing, indicating that factors in MS myelin influence
early-stage phagocytosis. Enhanced uptake was also ob-
served after 24 hours, at which time a plateau was reached
in the percentage of cells that phagocytosed myelin. We
also quantified myelin phagocytosis by primary human
microglia isolated from fresh postmortem human brain
tissue of 10 donors, which showed a more-linear increaseFigure 3 Increased uptake of MS myelin by primary human microglia
forward and sideward scatter (FSC and SSC) characteristics and the viability
24 hours of incubation. (B) Histograms showing uptake of 11 MS and 12 co
phagocytosed MS myelin more efficiently than control myelin after 24 hou
higher when cells were incubated with MS myelin. Shown is the mean of 1
Whitney U test. HC, healthy control; MS, multiple sclerosis.in myelin phagocytosis over 72-hours. Albeit the percent-
age of microglia that had phagocytosed MS versus control
myelin was the same, the total uptake of MS myelin was
higher compared with control myelin.
The age and PMD of MS and control donors differed
significantly, because myelin was isolated as donors
came to autopsy. Because age and PMD correlated with
myelin phagocytosis (negatively and positively, respect-
ively), we corrected for these parameters. Comparison ofafter 24 hours. (A) Flow-cytometric analysis of live cells defined by
dye eFluor were analyzed for uptake of pHrodo-labeled myelin after
ntrol myelin samples (pHrodo signal) after 24 hours. (C) Microglia
rs. The amount of myelin phagocytosed (geoMFI) was significantly
0 independent experiments. Data were analyzed with the Mann
Table 3 Comparison of phagocytosis of MS versus control









THP-1 (6 hours) Percentage 0.0010b 0.012a 0.0023b
GeoMFI 0.0005c 0.0016b 0.0082a
THP-1 (24 hours) Percentage 0.0006b 0.0004c 0.0082a
GeoMFI 0.0001c 0.0008b 0.0023b
Microglia (24 hours) Percentage 0.4791 0.3884 0.9452
GeoMFI 0.0106a 0.0496a 0.0734
GeoMFI, geomean fluorescence intensity; PMD, postmortem delay. aP < 0.05;
bP < 0.005; cP < 0.0005.
Comparison in uptake of MS versus control myelin by THP-1 macrophages
after 6 and 24 hours, and by primary human microglia after 24 hours,
expressed as the percentage of cells that had phagocytosed myelin and as the
amount of myelin taken up by the cells (geoMFI). Data were analyzed with the
Mann–Whitney U test. P values are provided for of all myelin samples, as well
as for age- and PMD-matched subgroups.
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or PMD-matched myelin samples still revealed a signifi-
cantly enhanced uptake of MS myelin in both cell types.
Significance was lost only in the PMD-matched myelin
samples taken up by primary microglia, but this was likely
because of loss of power caused by the smaller sample size,
and a trend remained detectable. We therefore conclude
that phagocytosis of MS myelin is more efficient than that
of control myelin, irrespective of donor age and PMD, pos-
sibly due to the changes in MS myelin already described in
literature [3-5,10-12,15,16,19-21,23-26] or to other yet-
unknown changes that may facilitate phagocytosis. Lipid
peroxidation did not influence phagocytosis in our experi-
ments and could thus not underlie the observed differences
in uptake. It would be very interesting to identify the targets
in MS myelin that cause its increased uptake. However, al-
though the differences in uptake are significant, they are
small, and the changes found previously in MS myelin are
numerous. We therefore considered identifying these tar-
gets beyond the scope of this article.
The role of microglia and infiltrating blood-borne mac-
rophages in myelin phagocytosis in MS is still debated
[32]. Depletion of infiltrating macrophages abolishes
neurologic symptoms in animal models of MS [33,34].
Conversely, rat and human microglia are better capable of
myelin phagocytosis than macrophages in vitro [10,35].
This study shows that isolated primary human microglia
are capable of myelin phagocytosis, but that they are
slower to start phagocytosing than THP-1 macrophages.
Unlike THP-1 macrophages, uptake by microglia was
more linear and did not reach a plateau within the time
frame studied. THP-1 macrophages phagocytosed either
negligible or large amounts of myelin, as can be concluded
from the two distinct populations detected after myelin in-
cubation with flow cytometry. In contrast, microglia
showed a more-gradual shift in pHrodo signal, indicatingthat most cells had taken up myelin. Of note, primary
microglia took up a large amount of myelin despite being
much smaller than THP-1 macrophages.
These results obtained with freshly isolated human
microglia indicate that microglia are indeed very capable
of contributing to myelin phagocytosis in MS, likely to-
gether with infiltrating macrophages. Previous research
has shown that microglia isolated from NAWM of MS
patients show an increased CD45 surface expression im-
mediately ex vivo compared with microglia from control
donors, indicating that microglia from MS patients are
alerted [30]. It would be interesting to investigate in a
future study whether MS microglia also differ in their
phagocytic capacity for myelin. Of note, an increase in
surface CD45 expression per se does not indicate a
higher phagocytic ability. In our populations, the initial
activation state did not correlate with myelin phagocyt-
osis, which also makes it unlikely that the neurologic
disease of the microglia donors that we investigated here
has influenced the results.
Interestingly, we found a dual age effect. Myelin isolated
from younger donors was phagocytosed more efficiently
than myelin isolated from older donors. Conversely, older
microglia increased their myelin phagocytic ability as mye-
lin phagocytosis showed a positive trend with the age of
microglia. Previous research showed that myelin degrad-
ation increased during aging in monkeys [36]. Further-
more, the incidence of dystrophic microglia, showing
abnormal morphology, increases during aging [37]. Func-
tionally, microglia from older mice phagocytosed less
amyloid β than did microglia from younger mice in an
Alzheimer disease model, which could explain why amyl-
oid β accumulates in the brain with age [38]. It is generally
accepted that microglia become slightly more proinflam-
matory during aging, which is usually associated with di-
minished phagocytic capacity [39,40]. However, a very
recent study suggests that microglia in mice show a shift
toward an alternative neuroprotective priming state to
compensate for the increased neuronal cell injury and
death and subsequent neurotoxicity during aging [41]. We
found a trend toward a positive correlation between the
age of microglia donors and myelin phagocytosis, indicat-
ing that the change in phagocytic capacity during aging
depends on the nature of the antigen. Collectively, these
data show that aging enhances the myelin phagocytic cap-
acity of microglia but reduces the myelin susceptibility for
phagocytosis. It remains to be shown whether the latter, in
conjunction with multiple sclerosis-specific changes, con-
tributes to the fact that MS usually establishes in young
adults [42] or even children [43].
Conclusions
We show that MS-derived myelin is taken up more effi-
ciently than control myelin, indicating that changes in
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is relatively small, it may be highly relevant, because
myelin was isolated from the NAWM of MS donors
where microglia are not actively demyelinating, and
myelin still visually appears unaffected. Importantly, this
indicates that the phagocytosis-inducing changes might
already occur early in disease pathology. Lesion onset is
thought to start with the activation and accumulation of
microglia [44,45], possibly reacting to changes in myelin.
The important next step will be to identify the changes
in the myelin from MS patients that promote phagocyt-
osis and investigate myelin-induced changes in myeloid
cells that facilitate myelin uptake in MS.Consent
Permission was obtained from donors for brain autopsy
and the use of tissue and clinical information for re-
search purposes.Additional files
Additional file 1: Microscopy of pHrodo-labeled myelin phagocyt-
osis by primary human microglia. Primary human microglia incubated
with pHrodo-labeled myelin for 72 hours. With phase-contrast microscopy,
large clumps of myelin are visible, but only phagocytosed myelin emits
fluorescent signal (63× magnification).
Additional file 2: Trend between myelin uptake and donor age of
10 primary human microglia isolates. Provided is the percentage of
cells that had phagocytosed myelin (upper panel) and the amount of
myelin taken up by the cells (geoMFI; lower panel) as the mean of all
myelin samples (blue dots), the MS myelin samples (red dots), and the
control myelin samples (green dots). Data were analyzed with the
Spearman rank correlation test. MS, multiple sclerosis; HC, healthy control.
Additional file 3: Analysis of myelin uptake in age- and PMD-matched
myelin samples. (A) Age and PMD of myelin donors differed significantly
between MS and control donors. (B) Both age and PMD correlated with
myelin phagocytosis, provided here as the percentage of cells that had
phagocytosed myelin and as the amount of myelin taken up by the cells
(geoMFI). (C) Correlation between myelin uptake (geoMFI) and age (left
panel) or PMD (right panel) was used to define subgroups of myelin
samples that matched for age and PMD (between the lines); shown here
for THP-1 macrophages after 24 hours of incubation with myelin. Open
black circles are control myelin samples. Closed red circles are MS myelin
samples. (D) Enhanced uptake (geoMFI) of MS myelin compared with HC
myelin in age- and PMD-matched subgroups by THP-1 macrophages
after 24 hours of incubation with myelin. A similar strategy was applied
for analyzing myelin uptake (percentage and total amount) by THP-1
macrophages after 6 hours of incubation and by primary human microglia
after 24 hours of incubation (not shown). A summary of all comparisons is
provided in Table 3. Data were analyzed with the Mann-Whitney U test. MS,
multiple sclerosis; HC, healthy control. * < 0.05; ** < 0.005; *** < 0.0005.
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